PEPFAR and Gilead partner to provide twice-yearly lenacapavir for HIV prevention in low-income countries

PEPFAR and Gilead will provide twice-yearly injectable HIV prevention drug lenacapavir to up to 2 million people in low-income countries. This no-profit agreement over three years aims to accelerate access to the long-acting PrEP option, lenacapavir, which is already approved in the US and EU. Lenacapavir is the first twice-yearly injectable PrEP, with regulatory submissions and WHO prequalification underway to ensure broad availability.